J-Pharma Launches New Clinical Trial FAQ Page

— Helping Readers Better Understand Our Clinical Trials —

November 4, 2026
J-Pharma Co., Ltd.

J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President and CEO: Masuhiro Yoshitake; hereinafter "J-Pharma" or the "Company") is pleased to announce the launch of a new "Clinical Trial FAQ (Frequently Asked Questions)" page within the Clinical Trials section of its website.

The new page provides clear and easy-to-understand answers to frequently asked questions about the clinical trials of drugs under development by the Company. It covers topics such as trial objectives, stages of development, and current progress.

The FAQ includes information on Beacon-BTC, the global Phase III clinical trial of nanvuranlat; an investigator-initiated clinical trial for biliary tract cancer; and the U.S. Phase I clinical trial of JPH034. It also provides information on research and development support from the Japan Agency for Medical Research and Development (AMED), along with explanations of terms commonly used in clinical trials.

J-Pharma will continue to provide clear and accurate information to help shareholders, investors, and other stakeholders better understand its research and development activities.

Clinical Trial FAQ Page
https://www.j-pharma.com/en/clinical_trial/faq/

Inquiries:
J-Pharma Co., Ltd.
Planning Department
TEL: +81-3-6432-4270
https://www.j-pharma.com/en/contact